Placebo + Sevelamer Carbonate (GZ419831)
Phase 3Completed 0 watching 0 views this week📈 Rising
76
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hyperphosphatemia
Conditions
Hyperphosphatemia
Trial Timeline
Jun 7, 2017 → Aug 16, 2019
NCT ID
NCT03001011About Placebo + Sevelamer Carbonate (GZ419831)
Placebo + Sevelamer Carbonate (GZ419831) is a phase 3 stage product being developed by Sanofi for Hyperphosphatemia. The current trial status is completed. This product is registered under clinical trial identifier NCT03001011. Target conditions include Hyperphosphatemia.
Hype Score Breakdown
Clinical
27
Activity
18
Company
9
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03001011 | Phase 3 | Completed |
Competing Products
20 competing products in Hyperphosphatemia